These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 33811541)

  • 1. An update: the emerging evidence of complement involvement in COVID-19.
    Li Q; Chen Z
    Med Microbiol Immunol; 2021 Jun; 210(2-3):101-109. PubMed ID: 33811541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19: Complement, Coagulation, and Collateral Damage.
    Lo MW; Kemper C; Woodruff TM
    J Immunol; 2020 Sep; 205(6):1488-1495. PubMed ID: 32699160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double edged-sword - The Complement System during SARS-CoV-2 infection.
    Santiesteban-Lores LE; Amamura TA; da Silva TF; Midon LM; Carneiro MC; Isaac L; Bavia L
    Life Sci; 2021 May; 272():119245. PubMed ID: 33609539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System.
    Lipcsey M; Persson B; Eriksson O; Blom AM; Fromell K; Hultström M; Huber-Lang M; Ekdahl KN; Frithiof R; Nilsson B
    Front Immunol; 2021; 12():627579. PubMed ID: 33692801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunothrombosis in Acute Respiratory Dysfunction of COVID-19.
    Fang XZ; Wang YX; Xu JQ; He YJ; Peng ZK; Shang Y
    Front Immunol; 2021; 12():651545. PubMed ID: 34149692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement as a target in COVID-19?
    Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD
    Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement Activation
    Niederreiter J; Eck C; Ries T; Hartmann A; Märkl B; Büttner-Herold M; Amann K; Daniel C
    Front Immunol; 2022; 13():835156. PubMed ID: 35237273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives.
    Boechat JL; Chora I; Morais A; Delgado L
    Pulmonology; 2021; 27(5):423-437. PubMed ID: 33867315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19: A collision of complement, coagulation and inflammatory pathways.
    Chauhan AJ; Wiffen LJ; Brown TP
    J Thromb Haemost; 2020 Sep; 18(9):2110-2117. PubMed ID: 32608159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps.
    Borges L; Pithon-Curi TC; Curi R; Hatanaka E
    Mediators Inflamm; 2020; 2020():8829674. PubMed ID: 33343232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.
    Root-Bernstein R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the COVID-19 thrombotic catastrophe complement-connected?
    Conway EM; Pryzdial ELG
    J Thromb Haemost; 2020 Nov; 18(11):2812-2822. PubMed ID: 32762081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement inhibition: A possible therapeutic approach in the fight against Covid-19.
    Deravi N; Ahsan E; Fathi M; Hosseini P; Yaghoobpoor S; Lotfi R; Pourbagheri-Sigaroodi A; Bashash D
    Rev Med Virol; 2022 Jul; 32(4):e2316. PubMed ID: 34873779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
    Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
    Front Immunol; 2022; 13():888897. PubMed ID: 35663932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.
    Gralinski LE; Sheahan TP; Morrison TE; Menachery VD; Jensen K; Leist SR; Whitmore A; Heise MT; Baric RS
    mBio; 2018 Oct; 9(5):. PubMed ID: 30301856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm.
    Chau AS; Weber AG; Maria NI; Narain S; Liu A; Hajizadeh N; Malhotra P; Bloom O; Marder G; Kaplan B
    Arthritis Rheumatol; 2021 Jan; 73(1):23-35. PubMed ID: 32929876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes.
    de Nooijer AH; Grondman I; Janssen NAF; Netea MG; Willems L; van de Veerdonk FL; Giamarellos-Bourboulis EJ; Toonen EJM; Joosten LAB;
    J Infect Dis; 2021 Feb; 223(2):214-224. PubMed ID: 33038254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement cascade in severe forms of COVID-19: Recent advances in therapy.
    Chouaki Benmansour N; Carvelli J; Vivier E
    Eur J Immunol; 2021 Jul; 51(7):1652-1659. PubMed ID: 33738806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19.
    Yen BL; Yen ML; Wang LT; Liu KJ; Sytwu HK
    Stem Cells Transl Med; 2020 Oct; 9(10):1163-1173. PubMed ID: 32526079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.